Biomarkers in development of psychotropic drugs

Dialogues in Clinical Neuroscience

Volumn 13, Issue 2, 2011, Pages 225-234

  Wiedemann, K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Biochemistry; Biomarker; Challenge study; Cytochrome enzyme; Genetics; Imaging; Neuroendocrinology; Sleep EEG; State; Trait

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BIOLOGICAL MARKER; DOPAMINE TRANSPORTER; NEUROLEPTIC AGENT; NORADRENALIN; PSYCHOTROPIC AGENT; SEROTONIN; PHARMACOLOGICAL BIOMARKER;

ANXIETY DISORDER; ARTICLE; BIOCHEMISTRY; DEPRESSION; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LABORATORY TEST; MENTAL DISEASE; NEUROENDOCRINOLOGY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENETICS; POSITRON; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; DIAGNOSTIC IMAGING; DRUG EFFECT; EPIGENETICS; GENETICS; METABOLISM; PATHOLOGY; REVIEW;

BIOMARKERS, PHARMACOLOGICAL; BRAIN; DIAGNOSTIC IMAGING; ELECTROENCEPHALOGRAPHY; EPIGENOMICS; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 80052142671     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Frank R, Hargreaves R Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2:566-580.
2. Möller HJ, Jäger M, Riedel M, Obermeier M, Strauss A, Bottlender R The Munich 15-year follow-up study (MUFSSAD) on first-hospitalized patients with schizophrenic or affective disorders: Assessing courses, types and time stability of diagnostic classification. Eur Psychiatry. 2010;196:460-466.
3. Lesko LJ, Atkinson AJ Jr Use of biomarkers and surrogate endpoints in drug development and regulatory decisionmaking: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001;41:347-366.
4. Spilker B Guide to Clinical Thais. 1996
5. Bieck PR, Potter WZ Biomarkers in psychotropic drug development: integration of data across multiple domains. Annu Rev Pharmacol Toxicol. 2005;45:227-246.
6. Schwarz E, Bahn S The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br J Pharmacol. 2008;153(suppl 1):S133-S136.
7. Leiser SC, Dunlop J, Bowlby MR, Devilbiss DM Aligning strategies for using EEG as a surrogate biomarker: aA review of preclinical andclinical research. Biochem Pharmacol. 2011;81:1408-1421.
8. Steiger A, Kimura M Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res. 2010;44:242-252.
9. Seier FE, Kellner M, Yassouridis A, Heese R, Strian F, Wiedemann K Autonomic reactivity and hormonal secretion in lactate-induced panik attacks. Am J Physiol. 1997;272:H2630-H638.
10. Hinkelmann K, Yassouridis A, Mass R, et al. CCK-4: pPsychophysiological conditioning elicits features of spontaneous panic attacks. J Psychiatr Res. 2010;44:1148-1153.
11. Hahn T, Marquand AF, Ehlis AC, Dresler T, et al. integrating neurobiological markers of depression. Arch Gen Psychiatry. 2010;68:361-368.
12. Wong DF, Gründer G, Brasic JR Brain imaging research: does the science serve clinical practice? Int Rev Psychiatry. 2007;19:541-558.
13. Kellner M, Knaudt K, Jahn H, Holsboer F, Wiedemann K Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine andpathophysiological consequences. J Psychiatr Res. 1998;32:37-48.
14. Kellner M, Muhtz C, Demiralay C, et al. The selective serotonin reuptake inhibitor excitalopram modulates the panic response tocholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype. J Psychiatr Res. 2009;43:642-648.
15. Harmer CJ, Cowen PJ, Goodwin GM Efficacy markers in depression. J Psychopharmacol.
16. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-389.
17. Risch N, Herrel R, Lehner T, Liang KY, et al. Interaction between the serotonin transporter gene 5-HTTLPR), stressful life events, and riskof depression: a meta-analysis. JAMA. 2009;301:2462-2471.
18. Fergusson DM, Norwood LJ, Miller AL, Kennedy MA Life stress, 5HTTLPR and mental disorder: findings from a 30-year longitudinal study. Br J Psychiatry. 2011;198:129-135.
19. Ising M, Lucae S, Binder EB, Bettecken T, et al. A genomewide association study points to multiple loci that predict antidepressant drugtreatment outcome in depression. Arch Gen Psychiatry. 2009;66:966-975.
20. Laje G, Perlis RH, Rush AJ, McMahon FJ Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv. 2009;60:1446-1457.
21. Horstmann S, Lucae S, Menke A, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010;35:727-740.
22. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804-814.
23. Domschke K, Lawford B, Laje G, et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. IntJ Neuropsychopharmacol. 2010;13:93-101.
24. Jacob C, Domschke K, Gajewska A, Warrings B, Deckert J Genetics of panic disorder: focus on association studies and therapeutic perspectives. Expert Rev Neurother. 2010;10:1273-1284.
25. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry. 2008;165:617-620.
26. Zoumakis E, Chrousos GP Corticotropin-releasing hormone receptor antagonists: an update. Endocr Dev. 2010;17:36-43.
27. Allen NC, Bagade S, McQueen MB, loannidis JP, et al. Systematic metaanalyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40:827-834.
28. Hennah W, Porteous D The DISC1 pathway modulates expression of neurodevelopmental, synaptogenic and sensory perception genes. PLoS One. 2009;4:e4906.
29. Foster A, Miller del D, Buckley P Pharmacogenetics and schizophrenia. Clin Lab Med. 2010;30:975-993.
30. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry. 2011;16:76-85.
31. Kirchheiner J, Seeringer A, Viviani R Pharmacogenetics in psychiatrya useful clinical tool or wishful thinking for the future? Curr Pharm Des. 2010;16:136-144.
32. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C Influence of cytochrome P450 polymorphisms on drug therapies: pharrnacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496-526.
33. Kirchheiner J, Rodriguez-Antona C Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs. 2009;23:181-191.
34. Arranz MJ, Kapur S Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull. 2008;34:1130-1144.
35. Hiemke C Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci. 2008;258(Suppl 1):21-27.
36. Fleeman N, Dundar Y, Dickson R, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 2011;11:1-14.
37. Ozaki N Pharmacogenetics of antipsychoatics. Nagoya J Med Sci. 2004;671-2:1-7.
38. Filiou MD, Turck CW, Martins-de-Souza D Quantitative proteomics for investigating psychiatric disorders. Proteomics Clin Appl. 2011;5:38-49.
39. Martins-de-Souza D, Maccarrone G, Wobrock T, et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res. 2010;44:1176-1189.
40. Raedler TJ, Wiedemann K CSF-studies in neuropsychiatrie disorders. A/euro Endocrinol Lett. 2006;27:297-305.
41. Mischak H, Schanstra JP CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl. 2011;5:9-23.
42. Refojo D, Holsboer F CRH signaling. Molecular specificity for drug targeting in the CNS. Ann N Y Acad Sci. 2009;1179:106-119.
43. Locatelli V, Bresciani E, Tamiazzo L, Torsello A Central nervous systemacting drugs influencing hypothalamic-pituitary-adrenal axis function. Endocr Dev. 2010;17:108-120.
44. Wiedemann K, Jahn H, Yassouridis A, Kellner M Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry. 2001;58:371-377.
45. Demiralay C, Jahn H, Kellner M, Yassouridis A, Wiedemann K Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men. Psychoneuroendocrinology. 2010;35:1438-1445.
46. De Kloet ER, Joels M, Holsboer F Stress and the brain: from adaption to disease. Nat Rev Neurosci. 2005;6:463-475.
47. Marques AH, Silverman MN, Sternberg EM Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics. Ann N Y Acad Sci. 2009;1179:1-18.
48. Ising M, Horstmann S, Kloiber S, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol Psychiatry. 2007;62:47-54.
49. Schüle C, Baghai TC, Eser D, et al. The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. PLoS One. 2009;4:e4324.
50. Paslakis G, Heuser I, Schweiger U, Deuschle M A single DEX/CRH test in male drug-free depressed patients is associated with the clinical response to treatment with fluoxetine. J Psychiatr Res. 2010;44:1154-1157.
51. Ising M, Kiinzel HE, Binder EB, Nickel T, Modell S, Holsboer F The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1085-1093.
52. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006;31:628-636.
53. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004;61:1235-1244.
54. Friess E, Schmid D, Modell S, et al. Dex/CRH-test response and sleep in depressed patients and healthy controls with and without vulnerability for affective disorders. J Psychiatr Res. 2008;42:1154-1162.
55. Rao U, Hammen CL, Poland RE Risk markers for depression in adolescents: sleep and HPA measures. Neuropsychopharmacology. 2009;34:1936-1945.
56. Murck H, Nickel T, Kiinzel H, et al. State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine. Neuropsychopharmacology. 2003;28:348-358.
57. Nutt D, Lawson C Panic attacks: a neurochemical overview of models and mechanisms. Br J Psychiatry. 1992;160:165-178.
58. Kellner M, Herzog L, Yassouridis A, Holsboer F, Wiedemann K Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic. Am J Psychiatry. 1995;152:1365-1367.
59. Gilles C, Luthringer R Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs. J Psychopharmacol. 2007;21:272-282.
60. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci. 1997;22:332-340.
61. Zwanzger P, Eser D, Aicher S, et al. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenalaxis activity: a placebo-controlled study. Neuropsychopharmacology. 2003;28:979-984.
62. Zwanzger P, Rupprecht R Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci. 2005;30:167-175.
63. Kramer MS, Cutler NR, Ballenger JC, et al. A placebo-controlled trial of L365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995;37:462-466.
64. van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van EsRadhakishun F, Pande AC The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology (Berl). 1997;129:243-248.
65. Gong Q, Wu Q, Scarpazza C, Lui S, et al. Prognostic prediction of therapeutic response in depression using high-field MR imaging. Neuroimage. 2011;55:1497-1503.
66. Dager SR, Corrigan NM, Richards TL, Posse S Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. Top Magn Reson Imaging. 2008;19:81-96.
67. Prêter M, Klein DF Panic, suffocation false alarms, separation anxiety and endogenous opioids. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:603-612.
68. Eser D, Leicht G, Lutz J, et al. Functional neuroanatomy of CCK-4induced panic attacks in healthy volunteers. Hum Brain Mapp. 2009;30:511-522.
69. Nord M, Farde L Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther.
70. Vyas NS, Patel NH, Nijran KS, Al-Nahhas A, Puri BK The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia. Expert Rev Neurother. 2011;11:37-51.